Skip to content

R&D at other companies

Baxter International logo
Baxter InternationalBAX
$139M-0.7%
Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
$249M+7.3%
ICU Medical logo
ICU MedicalICUI
$21.28M-8.6%
Haemonetics logo
HaemoneticsHAE
$14.45M-21.1%
Solventum logo
SolventumSOLV
$189M-2.1%
Medline, Inc.
 logo
Medline, Inc. MDLN
$20M+19.4%

Other financials

Income statement

See full
Revenue$309.9M+14.9%
Gross profit$140.4M+26.5%
Operating income$16.9M+245%
Net income$11.4M+262%
EPS (diluted)$0.25+267%

Balance sheet

See full
Cash & equivalents$291.0M-29.8%
Total debt$34.3M-23.1%
Total equity$1.3B0.0%
Total assets$2.0B-6.8%

Cash flow

See full
Operating cash flow$54.5M+110%
CapEx$12.4M+11.3%
Free cash flow$42.1M+185%

Valuation

See full
Market cap$1.8B-7.2%
Enterprise value$1.54B-0.4%
P/E116.4×
P/S1.5×-0.2×

Profitability

See full
Gross margin43.5%+0.4pp
Operating margin2.7%+1.8pp
Net margin1.7%+1.1pp
FCF margin9.3%-1.7pp

Returns & leverage

See full
Return on equity1.6%+1.1pp
Debt / equity0.0×
Current ratio1.5×+0.1×

Where this comes from

Reported directly by Omnicell in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Omnicell’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Omnicell's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Omnicell's R&D?
Omnicell (OMCL) reported R&D of $21.52M in Q1 2026.
How has Omnicell's R&D changed year-over-year?
Omnicell's R&D increased by 4.8% year-over-year, from $20.53M to $21.52M.
What is the long-term trend for Omnicell's R&D?
Over 4 years (2021 to 2025), Omnicell's R&D has grown at a 4.0% compound annual growth rate (CAGR), from $75.72M to $88.67M.
What does R&D mean?
Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.